Abstract Background and Aims Filgotinib is a small molecule that selectively inhibits Janus
kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is …

Introduction Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with
demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to …

Methods SELECTION (NCT02914522) was a randomized, placebo-controlled trial
comprising 2 induction studies and a maintenance study. Adults with moderately to severely …

Background The global prevalence of ulcerative colitis is increasing, and induction and
maintenance of remission is a crucial therapeutic goal. We assessed the efficacy and safety …

METHODS: In these post hoc analyses of the double-blinded, randomized, placebo-
controlled 58-week SELECTION trial (NCT02914522), rectal bleeding and stool frequency …

Abstract Background and Aims Ulcerative colitis [UC] impacts patients' health-related quality
of life [HRQoL]. We assessed HRQoL and an exploratory patient-level composite endpoint …

Summary Background Filgotinib 200 mg (FIL200) is an approved treatment for adults with
moderately to severely active ulcerative colitis (UC). Aim To report integrated safety data …

Summary Background Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered,
Janus kinase 1 (JAK1)-selective inhibitor. The FITZROY study examined the efficacy and …

Background Only one head-to-head comparison of advanced treatments in moderately to
severely active ulcerative colitis (UC) has been published; therefore, there remains a need …

The majority of patients have small bowel (SB) involvement with or without accompanying
colitis. 1 There is increasing evidence of differences in the biology of small bowel Crohn's …